Disclosures for "Causes of Rapidly Progressive Dementia in a Prospectively Accrued Cohort")
-
Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parabon Nanolabs. The institution of Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Barrow Law. Dr. Day has stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from Chan Zuckerberg Initiative. The institution of Dr. Day has received research support from Alzheimer's Association. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Horizon Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with American Academy of Neurology. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing Education, Inc. Dr. Day has a non-compensated relationship as a Clinical Director with AntiNMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.
-
Dr. Tipton has nothing to disclose.
-
Dr. Lazar has nothing to disclose.
-
Mr. Satyadev has received research support from National Academy of Medicine. Mr. Satyadev has received personal compensation in the range of $10,000-$49,999 for serving as a CEO with The Youth Movement Against Alzheimer's.
-
Dr. Martens has nothing to disclose.
-
Dr. Dunham has nothing to disclose.
-
Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LifeSci Capital LLC. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Blade Therapeutics, Inc. . Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clarion Consulting. Dr. Geschwind has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MedConnect ProLLC. The institution of Dr. Geschwind has received research support from NIH/NIA R01 AG AG031189. The institution of Dr. Geschwind has received research support from NIH/NIA R01 AG AG062562. The institution of Dr. Geschwind has received research support from Michael J. Homer Family Fund. The institution of Dr. Geschwind has received research support from NIH/NIA CADASIL RF1-R01. Dr. Geschwind has a non-compensated relationship as a Editorial Board with Dementia & Neuropsychologia that is relevant to AAN interests or activities.
-
Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CBR International Advisory Board. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cure Alzheimers Fund. Dr. Morris has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LEADS Steering Commitee. The institution of Dr. Morris has received research support from NIH grants. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care. Dr. Morris has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Novartis. The institution of Dr. Graff-Radford has received research support from AbbVie. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.